Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Drug-tolerant persisters, de novo mutations and pre-existing resistance are just some of the ways cancers evade the effects of anti-cancer drugs. Can new targets and new dosing strategies tackle evolutionary forces directly to delay the inevitable?
A massive, pioneering trial is underway to assess whether RNA-based modulation of Lp(a) — a form of bad cholesterol that narrows arteries, boosts the risk of blood clots and fans the flames of inflammation — can save lives.
Immunotherapies that activate costimulatory receptors on T cells have failed so far in the clinic, but the first phase III trial of an agonist antibody in cancer has just begun and second-generation candidates are advancing.
Nearly ten compounds from zebrafish screens are in or about to enter the clinic, and zebrafish 'avatars' are gaining traction as a tool to guide treatment plans for patients with cancers and rare diseases.
Target 2035 — an ambitious open-science proposal to develop a suite of chemical genomics tools to modulate every protein in the proteome — faces many challenges ahead.
Recursion, Janssen, insitro and others are combining high-content phenotypic screening with machine learning to zoom in on emerging opportunities in target discovery, hit identification, toxicity testing and more.
Small-molecule drugs and biologics that alter the microbiome or its interaction with host tissues are poised to change the face of microbiome therapeutics.
A long and growing list of anti-BCMA candidates — including chimeric antigen receptor-T cell therapies, antibody–drug conjugates and bispecific antibodies — are contending to transform multiple myeloma treatment.
Inhibitors of the innate immune system’s NLRP3 inflammasome promise potential in Parkinson disease, Alzheimer disease, non-alcoholic steatohepatitis, gout and much more, catching the eye of Novartis, Genentech and others.
New therapeutics that harness cellular machinery to degrade targets are entering clinical trials, led by a PROTAC anticancer candidate developed by Arvinas.